Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Advanced Salivary Gland Cancers
NCT06805617Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in salivary gland cancer (SGC), sponsored by Dana-Farber Cancer Institute. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT06805617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06805617.